Flax Pond Capital LLC Buys Shares of 797,246 FocalTherics $FOCL

Flax Pond Capital LLC bought a new position in FocalTherics (NASDAQ:FOCL) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 797,246 shares of the company’s stock, valued at approximately $2,623,000. FocalTherics makes up approximately 1.9% of Flax Pond Capital LLC’s investment portfolio, making the stock its 24th largest holding. Flax Pond Capital LLC owned about 2.13% of FocalTherics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of FOCL. Financial Planning Navigators CORP purchased a new stake in shares of FocalTherics during the fourth quarter valued at $33,000. Kovack Advisors Inc. purchased a new position in FocalTherics in the 4th quarter worth about $53,000. Rock Springs Capital Management LP lifted its stake in FocalTherics by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after acquiring an additional 16,500 shares during the period. Finally, Leonteq Securities AG purchased a new stake in shares of FocalTherics during the 4th quarter valued at about $313,000. 62.74% of the stock is owned by institutional investors.

Insider Buying and Selling at FocalTherics

In related news, Director Joshua Levine acquired 10,000 shares of the stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $4.22 per share, with a total value of $42,200.00. Following the transaction, the director directly owned 35,000 shares in the company, valued at approximately $147,700. This represents a 40.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on FOCL shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, FocalTherics has an average rating of “Hold” and a consensus target price of $6.00.

FocalTherics Price Performance

NASDAQ:FOCL opened at $4.81 on Friday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. FocalTherics has a one year low of $1.21 and a one year high of $5.05.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $20.48 million for the quarter, compared to analysts’ expectations of $19.46 million. FocalTherics had a negative net margin of 41.47% and a negative return on equity of 137.61%. On average, equities research analysts predict that FocalTherics will post -0.78 earnings per share for the current fiscal year.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.